肌萎缩侧索硬化症:综述
约85%为散发性,15%为家族性;确诊后平均生存3至5年,目前无治愈疗法。美国FDA批准三种疾病修饰疗法:利鲁唑和依达拉奉口服可延缓进展最多2至4个月,托夫生为SOD1变异患者的鞘内基因治疗;多学科团队管理可改善生存(4至7个月)和生活质量。
要点
- ALS表现为局灶起病的进行性无痛性肌无力,可累及肢体(65%)、颅肌(20%-25%)或轴肌(5%-10%)。
- 诊断基于临床特征,肌电图可辅助;超过60个基因相关,多为常染色体显性。
- 利鲁唑和依达拉奉口服延缓进展最多2至4个月,托夫生用于SOD1变异患者。
核心结论
- ALS是进行性致死性上下运动神经元神经退行性疾病,目前无治愈疗法。
- 利鲁唑和依达拉奉可适度延缓散发性ALS进展,托夫生减缓SOD1致病变异患者的进展。
研究设计与样本
- 综述,未报告系统检索范围或样本量。
主要发现
- 起病表现为肢体无力占65%,颅肌无力占20%-25%,轴肌无力占5%-10%。
- 确诊后平均生存3至5年。
- 超过60个基因与ALS相关,多数为常染色体显性;C9orf72致病变异见于40%家族性ALS,SOD1致病变异见于20%家族性ALS患者。
关键数值与推荐
- 利鲁唑和依达拉奉口服可延缓ALS进展最多2至4个月。
- 托夫生为鞘内给药的基因治疗,用于SOD1基因变异患者。
- 多学科团队管理与生存改善4至7个月及生活质量提高相关。
临床怎么用
- 临床 care 以症状管理和生活质量为主,可选用三种FDA批准的疾病修饰疗法。
- 推荐多学科团队(神经科医生、护士、治疗师、营养师、社工)参与管理。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive weakness due to degeneration of upper motor neurons in the brain and lower motor neurons in the brainstem and spinal cord. It affects approximately 25 000 individuals in the United States. OBSERVATIONS: Amyotrophic lateral sclerosis is characterized by progressive painless muscle weakness that typically begins in a focal region of the body, such as limb muscle weakness causing hand weakness or foot drop (65%), cranial muscle weakness causing speech or swallowing problems (20%-25%), or axial muscle weakness causing bent posture (5%-10%), and spreads to other body regions over time. The disease usually manifests with dysfunction indicative of both upper motor neurons (causing muscle stiffness and spasticity) and lower motor neurons (causing weakness, fasciculations, atrophy, and flaccidity). After onset, weakness spreads through the musculature and typically causes death due to respiratory muscle weakness. Among people with ALS, approximately 85% have sporadic ALS, which is not associated with known environmental or genetic factors, and 15% have familial ALS. Amyotrophic lateral sclerosis is diagnosed based on clinical features, which can be supported by results of electromyography. More than 60 genes have been associated with ALS, and most are autosomal dominant. Pathogenic variants in chromosome 9 open reading frame 72 (C9orf72) are found in 40% of all familial ALS cases, and pathogenic variants in superoxide dismutase 1 (SOD1) are found in 20% of patients with familial ALS. Patients with ALS survive a mean of 3 to 5 years after diagnosis, and there are currently no curative therapies. Clinical care primarily focuses on symptom management and quality of life. Three US Food and Drug Administration (FDA)-approved disease-modifying therapies are available in the United States. Riluzole and edaravone are oral medications that slow ALS progression by up to 2 to 4 months, and tofersen is an intrathecally administered gene therapy for patients with SOD1 gene variants. Specialized multidisciplinary teams, comprising neurologists, nurses, therapists, dietitians, and social workers, are associated with improved survival (4-7 months) and quality of life. CONCLUSIONS AND RELEVANCE: Amyotrophic lateral sclerosis is a progressive and fatal neurodegenerative disorder of upper and lower motor neurons. No curative therapies exist. Two oral medications, riluzole and edaravone, are approved by the FDA and modestly decrease disease progression in sporadic ALS. Tofersen, an intrathecally administered gene-based therapy, is also FDA approved and slows disease progression in patients with SOD1 pathogenic gene variants.
引用
- Ravits J, Ferrey D, Gundogdu B, et al. Amyotrophic Lateral Sclerosis: A Review. JAMA. 2026. PMID: 42113599. doi:10.1001/jama.2026.6385
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。